Dyania Health is a technology company.
Dyania Health has raised $5.0M across 1 funding round.
Dyania Health has raised $5.0M in total across 1 funding round.
Dyania Health has raised $5.0M in total across 1 funding round.
Dyania Health's investors include .406 Ventures, Glasswing Ventures, Innospark Ventures.
Dyania Health is a healthcare AI company founded in 2019 that builds Synapsis AI, a proprietary large language model (LLM)-based platform automating electronic medical record (EMR) review.[1][2][4] It serves healthcare systems, physicians, pharmaceutical sponsors, and researchers by processing structured and unstructured EMR data in under 0.5 seconds—tasks that take humans 30 minutes or more—with ~95% accuracy, outperforming medical professionals.[1][6][8] The platform solves manual chart review inefficiencies for clinical trial pre-screening, observational studies, registry reporting, therapeutic gap identification, quality of care measurement, and evidence-based care pathways, enabling faster patient matching, precision medicine, and reduced trial timelines.[1][3][7] With 21-50 employees, offices in Jersey City, NJ, and Athens, Greece, and $10M in recent funding, Dyania shows strong growth momentum through partnerships with large healthcare systems and pharma, scaling engineering and AI capabilities.[4][6]
Dyania Health was founded in 2019 by Eirini Schlosser, its CEO, as a female-founded venture addressing manual EMR abstraction challenges.[2][4][6] Schlosser, with a background in healthcare AI development spanning a decade, led the creation of Synapsis AI to handle complex, inconsistent medical data at scale.[2] The idea emerged from recognizing that human review of EMRs—for clinical trials or care optimization—was too slow and error-prone, prompting a computational platform blending natural language processing (NLP), machine learning, and physician input.[5][8] Early traction came via Endeavor Greece selection in 2022, validation from in-house clinicians for LLM training, and deployment in diverse U.S. and global therapeutic areas, including oncology and cardiology.[1][4][8] Pivotal moments include raising $10M to expand AI and partnerships, revolutionizing trial patient matching.[3][6]
Dyania rides the AI-in-healthcare wave, leveraging LLMs for NLP on unstructured EMRs amid exploding data volumes and clinician burnout from manual reviews.[2][4][6] Timing aligns with post-2020 AI advancements and regulatory pushes for faster trials (e.g., FDA emphasis on diversity/recruitment), where 80-90% of trials fail on enrollment delays—Synapsis cuts this by automating matching for hard-to-find patients.[1][3] Market forces like rising pharma R&D costs ($2.6B/trial average), payer demands for evidence-based care, and enterprise AI adoption favor Dyania, influencing the ecosystem by boosting trial efficiency, patient access to therapies, and real-world evidence generation.[6][7] As part of Motivate VC's portfolio and Endeavor-backed, it accelerates AI precision medicine, competing with firms like Iterative Health while expanding to autoimmune, oncology, and cardiology.[1][2][3]
Dyania Health is poised to dominate AI-driven EMR automation, with next steps focusing on engineering scale-up, deeper pharma/health system integrations, and proprietary LLM enhancements for rare diseases and diagnostics.[4][6][8] Trends like multimodal AI, federated learning for privacy, and value-based care will propel growth, potentially capturing share in the $50B+ clinical trial market. Its influence may evolve from trial enabler to enterprise care optimizer, empowering global patient outcomes as AI maturity reduces skepticism. This positions Dyania as a transformative force, directly tackling healthcare's data bottleneck to unlock faster, equitable innovation.[1][7]
Dyania Health has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $5.0M Seed | .406 Ventures, Glasswing Ventures, Innospark Ventures |